ReviewTranslational gastroenterology and hepatology2026
Gut microbiota profile and response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review.
Review in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rectal cancer (RC) accounts for approximately 30% of all colorectal cancers, with pathological complete response (pCR) rates following neoadjuvant chemoradiotherapy (nCRT) ranging from 10-15% and reaching up to 38% with total neoadjuvant therapy. The intestinal microbiota has emerged as a potential modulator of treatment efficacy, offering opportunities for patient stratification and personalized therapy. This review aimed to the best of our knowledge, no robust systematic review has focused on the microbiota profile as a biomarker of response to nCRT in RC. Most studies focus on the effect of the microbiota on the adjuvant response to chemotherapy. To synthesize the available evidence and fill the gap in knowledge on the role of the intestinal microbiota in modulating treatment response and prognosis in patients with RC undergoing nCRT. Methods: This systematic review was registered in PROSPERO (CRD420251174787). A comprehensive search was conducted across PubMed, PubMed Central (PMC), Virtual Health Library (BVS), Scopus, Web of Science, Embase, and Cochrane Library. Studies evaluating the association between the intestinal microbiota and treatment response or prognosis in adult patients with RC were included. Two independent reviewers selected studies, and data were extracted from eligible studies. Results: Seventeen studies were included, all published after 2020, with 11 published between 2023 and 2025. Most studies originated from China (11/17). Sequencing methodologies included 16S rRNA sequencing (9 studies), shotgun metagenomics (6 studies), RNA-sequencing (2 studies), and whole-exome sequencing with Path-seq (1 study). A total of 868 patients were evaluated. Alpha-diversity did not differ significantly between responders and non-responders in most studies. Beta-diversity results were heterogeneous. Responders were associated with genera such as Conclusions: The intestinal microbiota may play a relevant role in modulating response to nCRT in RC, particularly through functional metabolic pathways rather than taxonomic composition alone. Predictive models based on microbial signatures show promising accuracy, although standardization of methodologies and validation in diverse populations are needed before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.